메뉴 건너뛰기




Volumn 82, Issue 9, 1998, Pages 1720-1725

CA 125 may not reflect disease status in patients with uterine serous carcinoma

Author keywords

CA 125; Chemotherapy; Endometrial carcinoma; Tumor markers; Uterine carcinoma; Uterine serous carcinoma

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

EID: 0032080734     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1720::AID-CNCR19>3.0.CO;2-6     Document Type: Article
Times cited : (45)

References (12)
  • 1
    • 0020559574 scopus 로고
    • A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer
    • Bast RC Jr., Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309(15):883-7.
    • (1983) N Engl J Med , vol.309 , Issue.15 , pp. 883-887
    • Bast Jr., R.C.1    Klug, T.L.2    St. John, E.3    Jenison, E.4    Niloff, J.M.5    Lazarus, H.6
  • 2
    • 0022596973 scopus 로고
    • Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer
    • Einhorn N, Bast RC Jr., Knapp RC, Tjernberg B, Zurawski VR Jr. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 1986;67(3):414-6.
    • (1986) Obstet Gynecol , vol.67 , Issue.3 , pp. 414-416
    • Einhorn, N.1    Bast Jr., R.C.2    Knapp, R.C.3    Tjernberg, B.4    Zurawski Jr., V.R.5
  • 3
    • 0023929166 scopus 로고
    • Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses
    • Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988;72(1):23-7.
    • (1988) Obstet Gynecol , vol.72 , Issue.1 , pp. 23-27
    • Chen, D.X.1    Schwartz, P.E.2    Li, X.G.3    Yang, Z.4
  • 4
    • 0029862921 scopus 로고    scopus 로고
    • CA 125: An evolving role in the management of ovarian cancer
    • Markman M. CA 125: an evolving role in the management of ovarian cancer [editorial]. J Clin Oncol 1996;14(5):1411-2.
    • (1996) J Clin Oncol , vol.14 , Issue.5 , pp. 1411-1412
    • Markman, M.1
  • 5
    • 0028236178 scopus 로고
    • Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma
    • Rose PG, Sommers RM, Reale FR, Hunter RE, Fournier L, Nelson BE. Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. [review]. Obstet Gynecol 1994;84(1):12-6.
    • (1994) Obstet Gynecol , vol.84 , Issue.1 , pp. 12-16
    • Rose, P.G.1    Sommers, R.M.2    Reale, F.R.3    Hunter, R.E.4    Fournier, L.5    Nelson, B.E.6
  • 6
    • 0024322579 scopus 로고
    • CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma
    • Tseng PC, Sprance HE, Carcangiu ML, Chambers JT, Schwartz PE. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma. Obstet Gynecol 1989;74(3 Pt 1):384-7.
    • (1989) Obstet Gynecol , vol.74 , Issue.3 PART 1 , pp. 384-387
    • Tseng, P.C.1    Sprance, H.E.2    Carcangiu, M.L.3    Chambers, J.T.4    Schwartz, P.E.5
  • 7
    • 0027733830 scopus 로고
    • Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC)
    • Price FV, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol Oncol 1993;51(3):383-9.
    • (1993) Gynecol Oncol , vol.51 , Issue.3 , pp. 383-389
    • Price, F.V.1    Chambers, S.K.2    Carcangiu, M.L.3    Kohorn, E.I.4    Schwartz, P.E.5    Chambers, J.T.6
  • 8
    • 10244261646 scopus 로고    scopus 로고
    • Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers
    • Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88(20):1456-66.
    • (1996) J Natl Cancer Inst , vol.88 , Issue.20 , pp. 1456-1466
    • Hayes, D.F.1    Bast, R.C.2    Desch, C.E.3    Fritsche, H.4    Kemeny, N.E.5    Jessup, J.M.6
  • 9
    • 0023938229 scopus 로고
    • The role of CA 125 in the evaluation of palpable or enlarged postmenopausal ovaries
    • Schwartz PE. The role of CA 125 in the evaluation of palpable or enlarged postmenopausal ovaries. Am J Obstet Gynecol 1988;158(5):1072-3.
    • (1988) Am J Obstet Gynecol , vol.158 , Issue.5 , pp. 1072-1073
    • Schwartz, P.E.1
  • 10
    • 0029961618 scopus 로고    scopus 로고
    • Denning response of ovarian carcinoma to initial chemotherapy according to serum CA 125
    • Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, et al. Denning response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996;14(5):1545-51.
    • (1996) J Clin Oncol , vol.14 , Issue.5 , pp. 1545-1551
    • Rustin, G.J.1    Nelstrop, A.E.2    McClean, P.3    Brady, M.F.4    McGuire, W.P.5
  • 12
    • 0026476737 scopus 로고
    • False-positive elevation of CA 125 in papillary serous carcinoma of the endometrium treated with postoperative whole abdominal radiation
    • Rose PG, Nelson BE, Reale FR. False-positive elevation of CA 125 in papillary serous carcinoma of the endometrium treated with postoperative whole abdominal radiation. Gynecol Oncol 1992;47(1):127-9.
    • (1992) Gynecol Oncol , vol.47 , Issue.1 , pp. 127-129
    • Rose, P.G.1    Nelson, B.E.2    Reale, F.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.